NO20043832L - Oral fast losningsformulering av en darlig vannloselig aktiv substans - Google Patents

Oral fast losningsformulering av en darlig vannloselig aktiv substans

Info

Publication number
NO20043832L
NO20043832L NO20043832A NO20043832A NO20043832L NO 20043832 L NO20043832 L NO 20043832L NO 20043832 A NO20043832 A NO 20043832A NO 20043832 A NO20043832 A NO 20043832A NO 20043832 L NO20043832 L NO 20043832L
Authority
NO
Norway
Prior art keywords
active substance
solid solution
poorly water
oral solid
soluble active
Prior art date
Application number
NO20043832A
Other languages
English (en)
Norwegian (no)
Inventor
Henricus R M Gorissen
Original Assignee
Solvay Pharm Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Bv filed Critical Solvay Pharm Bv
Publication of NO20043832L publication Critical patent/NO20043832L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20043832A 2002-02-14 2004-09-13 Oral fast losningsformulering av en darlig vannloselig aktiv substans NO20043832L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02075623 2002-02-14
PCT/EP2003/050014 WO2003068266A1 (en) 2002-02-14 2003-02-11 Oral solid solution formulation of a poorly water-soluble active substance

Publications (1)

Publication Number Publication Date
NO20043832L true NO20043832L (no) 2004-09-13

Family

ID=27619166

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20043832A NO20043832L (no) 2002-02-14 2004-09-13 Oral fast losningsformulering av en darlig vannloselig aktiv substans

Country Status (25)

Country Link
US (2) US20050008697A1 (es)
EP (1) EP1476196B1 (es)
JP (1) JP2005517041A (es)
KR (1) KR101014545B1 (es)
CN (1) CN1273194C (es)
AR (1) AR038681A1 (es)
AT (1) ATE345817T1 (es)
AU (1) AU2003208713B2 (es)
BR (1) BR0307278A (es)
CA (1) CA2472744A1 (es)
DE (1) DE60309839T2 (es)
DK (1) DK1476196T3 (es)
ES (1) ES2277635T3 (es)
HK (1) HK1077218A1 (es)
HR (1) HRP20040613A2 (es)
IL (2) IL162883A0 (es)
MX (1) MXPA04007852A (es)
NO (1) NO20043832L (es)
PL (1) PL370452A1 (es)
PT (1) PT1476196E (es)
RU (1) RU2314811C2 (es)
SI (1) SI1476196T1 (es)
UA (1) UA79267C2 (es)
WO (1) WO2003068266A1 (es)
ZA (1) ZA200405608B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004062692A1 (en) * 2003-01-13 2004-07-29 Solvay Pharmaceuticals B.V. Formulation of poorly water-soluble active substances
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US20050267124A1 (en) * 2004-05-14 2005-12-01 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous producing system and PDEV inhibiitors
TW200633713A (en) * 2004-12-23 2006-10-01 Solvay Pharm Bv Oral immediate release formulation of a poorly water-soluble active substance
US20060159748A1 (en) * 2004-12-23 2006-07-20 Rajesh Jain Oral immediate release formulation of a poorly water-soluble active substance
WO2007054975A1 (en) * 2005-11-08 2007-05-18 Panacea Biotec Ltd Pharmaceutical compositions for the treatment of cardiovascular and other associated disorders
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
JP2007308479A (ja) 2006-04-20 2007-11-29 Shin Etsu Chem Co Ltd 固体分散体製剤
EA014898B1 (ru) * 2006-06-16 2011-02-28 Солвей Фармасьютикалс Б.В. Пероральная фармацевтическая композиция из активного вещества, плохо растворимого в воде
AU2007263016A1 (en) * 2006-06-22 2007-12-27 Panacea Biotec Ltd. Oral pharmaceutical composition of a poorly water-soluble active substance
EP2037897B1 (en) * 2006-07-06 2011-03-30 Ares Trading S.A. An oral pharmaceutical composition of an anilinopyrimidine, its preparation and use thereof
US20080181959A1 (en) * 2006-09-01 2008-07-31 Ilan Zalit Solid composites of a calcium receptor-active compound
AR071375A1 (es) * 2008-04-22 2010-06-16 Solvay Pharm Gmbh Formulaciones para ingredientes farmaceuticos activos de permeabilidad deficiente, proceso de preparacion y producto
WO2010144865A2 (en) 2009-06-12 2010-12-16 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
US20120034297A1 (en) 2010-08-04 2012-02-09 Gruenenthal Gmbh Pharmaceutical dosage forms comprising 6'-fluoro-(N-methyl- or N,N-dimethyl-)-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine
LT2600839T (lt) * 2010-08-04 2018-03-26 GrĆ¼nenthal GmbH Vaistinė dozavimo forma, apimanti 6'-fluor-(n-metil- arba n,n-dimetil-)-4-fenil-4',9'-dihidro-3'h-spiro[cikloheksan-1,1'-pirano[3,4,b]indol]-4-aminą
CN107735080B (zh) * 2015-07-03 2020-10-23 浙江海正药业股份有限公司 一种人参皂苷c-k口服固体制剂及其制备方法
PL424452A1 (pl) 2018-01-31 2019-08-12 Forty-Four Pharmaceuticals Spółka Z Ograniczoną Odpowiedzialnością Inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP) do profilaktyki i leczenia chorób oczu
IL283450B1 (en) * 2018-11-30 2024-02-01 Chemocentryx Inc Solid solution capsule formulations containing (3S,2R)-2-(4-(cyclopentylamino)phenyl)-1-(2-fluoro-6-methylbenzoyl)-N-(4-methyl-3-(trifluoromethyl)phenyl) Piperidine-3-carboxamide, methods for their preparation and their medical uses

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3359167A (en) * 1965-07-22 1967-12-19 Pfizer & Co C Vitamin a compositions
US4325970A (en) * 1980-10-09 1982-04-20 Hoffmann-La Roche Inc. 15-Acetyl-prostaglandins
NZ224497A (en) * 1987-05-18 1990-04-26 Janssen Pharmaceutica Nv Pharmaceutical composition comprising flunarizine
US5281420A (en) * 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
DE19510566A1 (de) * 1995-03-23 1996-09-26 Kali Chemie Pharma Gmbh Benzazepin-, Benzoxazepin- und Benzothiazepin-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19638020A1 (de) * 1996-09-18 1998-03-19 Solvay Pharm Gmbh Die gastrointestinale Durchblutung fördernde Arzneimittel
TW426516B (en) * 1996-12-06 2001-03-21 Fujisawa Pharmaceutical Co An oral pharmaceutical composition in solid dispersion containing water-insoluble tricyclic compounds
EP0988046B1 (en) * 1997-01-30 2004-09-15 Novartis AG Oil-free pharmaceutical compositions containing cyclosporin a
US6008191A (en) * 1997-09-08 1999-12-28 Panacea Biotec Limited Pharmaceutical compositions containing cyclosporin
KR100336090B1 (ko) * 1998-06-27 2002-05-27 윤승원 오일, 지방산 또는 이들의 혼합물을 함유한 난용성 약물의 고형분산제제
DE19906310A1 (de) * 1999-02-16 2000-08-17 Solvay Pharm Gmbh Arzneimittel zur Behandlung von Bluthochdruck
DE19932555A1 (de) * 1999-07-13 2001-01-18 Solvay Pharm Gmbh Arzneimittel mit protektiver Wirkung gegen oxidativ-toxische und insbesondere gegen kardiotoxische Substanzen
US20010036959A1 (en) * 2000-04-03 2001-11-01 Gabel Rolf Dieter Carvedilol-hydrophilic solutions

Also Published As

Publication number Publication date
ES2277635T3 (es) 2007-07-16
ZA200405608B (en) 2005-06-24
US20110086844A1 (en) 2011-04-14
WO2003068266A1 (en) 2003-08-21
RU2004127457A (ru) 2005-04-20
IL162883A (en) 2009-05-04
JP2005517041A (ja) 2005-06-09
AU2003208713A1 (en) 2003-09-04
HRP20040613A2 (en) 2005-04-30
AR038681A1 (es) 2005-01-26
DE60309839D1 (de) 2007-01-04
AU2003208713B9 (en) 2003-09-04
ATE345817T1 (de) 2006-12-15
AU2003208713B2 (en) 2007-10-18
CN1273194C (zh) 2006-09-06
RU2314811C2 (ru) 2008-01-20
PL370452A1 (en) 2005-05-30
BR0307278A (pt) 2004-12-28
KR20040085193A (ko) 2004-10-07
KR101014545B1 (ko) 2011-02-16
US20050008697A1 (en) 2005-01-13
DK1476196T3 (da) 2007-03-05
MXPA04007852A (es) 2004-10-15
DE60309839T2 (de) 2007-03-15
CA2472744A1 (en) 2003-08-21
HK1077218A1 (en) 2006-02-10
SI1476196T1 (sl) 2007-04-30
CN1633307A (zh) 2005-06-29
EP1476196B1 (en) 2006-11-22
EP1476196A1 (en) 2004-11-17
PT1476196E (pt) 2007-02-28
IL162883A0 (en) 2005-11-20
UA79267C2 (en) 2007-06-11

Similar Documents

Publication Publication Date Title
NO20043832L (no) Oral fast losningsformulering av en darlig vannloselig aktiv substans
FI7617U1 (fi) Amorfisen aktiivisen ainesosan stabiloitu farmaseuttinen valmiste
NO20043866L (no) Farmasoytisk formulering av IRESSA omfattende et vannopploselig cellulosederivat
NO20053076D0 (no) Farmasoytisk formulering med en uloselig aktiv forbindelse.
CY2018005I2 (el) Απο του στοματος φαρμακοτεχνικες μορφες της κλαντριβινης
DK2258394T3 (da) Oral doseringsform omfattende en PDE 4-inhibitor som en aktiv bestanddel og polyvinylpyrrolidon som excipiens
NO20033343D0 (no) Farmasöytiske doseringsformer av epothiloner for oral administrasjon
DK1545467T3 (da) Faste farmaceutiske formuleringer omfattende telmisartan
PT1501534E (pt) Formulacoes farmaceuticas
AU2003229555A1 (en) Oral administration form for difficulty soluble basic active ingredients which are applied orally
NO20042842L (no) Farmasoytiske formuleringer av platina-derivat
ATE307571T1 (de) Pharmazeutische formulierung enthaltend bicalutamid
NO20055631L (no) Doseringsform inneholdende pantoprazol som aktiv ingrediens
FR2904219B1 (fr) Microparticules a base de copolymere amphiphile et de principe(s) actif(s) a liberation modifiee et formulations pharmaceutiques en contenant
NO20026209L (no) Endoparasitticidale midler for frivillig oralt inntak av dyr
ATE388703T1 (de) Pharmazeutische formulierung des telmisartan natriumsalzes
DE60336999D1 (de) Melatonin enthaltende pharmazeutische formulierung
FR2852845B1 (fr) Compositions pharmaceutiques a activite antibiotique
PL1848439T3 (pl) Doustna formulacja o natychmiastowym uwalnianiu słabo rozpuszczalnej w wodzie substancji aktywnej
DK1666473T3 (da) Carboxylsyreforbindelser og medicinske sammensætninger indeholdende samme som aktiv ingrediens
NO20043633L (no) Oral doseringsform for kontrollert medikamentfrigivning
DE502004003170D1 (de) Schmelzformulierte, multipartikuläre orale darreichungsform enthaltend clavulansäure
NO20032581D0 (no) Farmasöytisk formulering av gepiron for oral administrering
AU2003302888A1 (en) Oral formulations for poorly absorptive hydrophilic drugs
IL183554A0 (en) Oral immediate formulation of a poorly watersoluble active substance

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application